Even if PCSK9 inhibitors demonstrate strong lipid-lowering efficacy, achieving an average LDL-C reduction of 47.8% versus placebo in individuals with T1D [44], the evidence for CVD prevention in T1D is limited, as 97% of participants in key studies had T2D. This evidence concerns the gene PCSK9 and type 2 diabetes mellitus.